Clinical Trial Update: Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating eltrombopag for thrombocytopenia in patients with low- to intermediate-risk myelodysplastic syndromes (MDS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: Associazione Qol-one | Conditions: Myelodysplastic Syndromes, Thrombocytopenia | Phase 2 | Status: ACTIVE_NOT_RECRUITING